Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
China
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong Harbin Medical university cancer hospital, Harbin, Heilongjiang Jiangxi Cancer Hospital, Nanchang, Jiangxi Shanghai east hospital, Shanghai, Shanghai Municipality Yunnan Cancer Hospital, Kunming, Yunnan